|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacokineties, pharmacodynamlcs and safety of febuxostar, a non- purine selective inhibitor of xanthine oxidase, in a close escalation study in healthy subjects显示文摘 | Khosravan R Grabowski BA Wu JT | 2006 | Clin Pharmacoki net2006，45，8： | 1 |
| 2 | Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects 显示文摘 | Khosravan R Grabowski BA Wu JT | 2006 | Clin Pharmacokinet2006，45，8： | 1 |
| 3 | Metabolism and excretion of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in healthy male subjects 显示文摘 | GRABOWSKI BA VERNILLET L KHOSRAVAN R | 2005 | Drug Metab Rev2005，37，2： | 1 |
| 4 | The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodyaamics, and safety of febnxostat, a novel non- purine selective inhibitor of xanthine oxidase 显示文摘 | KHOSRAVAN R GRABOWSKI BA MAYER MD | 2006 | J Clin Pharmacol2006，46，1： | 1 |
| 5 | Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects显示文摘 | Khosravan R Grabowski BA Wu JT | 2008 | Br J CIin Pharmacol2008，65，3： | 1 |
| 6 | Pharmacokinetics, phar- macodynamics and safety of febuxostat, a non - purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects显示文摘 | Khosravan R Grabowski BA Wu JT | 2006 | Clin Pharmacokinet2006，45，： | 1 |
| 7 | The effect of mild and moderate hepatic impairment on pharmacokinetics,pharmacodynamics,and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase显示文摘 | Khosravan R Grabowski BA Mayer MD | 2006 | J Clin Pharmacol2006，46，： | 1 |
| 8 | Pharmacokinetics,pharmacodynamics and safety of febuxostat,a non-purine selective inhibitor of xanthine oxidase,in a dose escalation study in healthy subjects显示文摘 | Khosravan R Grabowski BA Wu JT | 2006 | Clin Pharmacokinet2006，45，： | 1 |
| 9 | Theeffect of mild and moderate hepatic impairment onpharmacokinetics, pharmacodynamics, and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase显示文摘 | KHOSRAVAN R GRABOWSKI BA MAYER MD et d | 2006 | J ClinPharmacol2006，46，1： | 1 |
| 10 | Pharmacokinetics,pharmacodynamics and safety of febuxostat,anon purine selective inhibitor of xanthine oxidase,in a doseescalation study in healthy subjects显示文摘 | KHOSRAVAN R GRABOWSKI BA WU JT | 2006 | Clin Pharmacokinet2006，45，8： | 1 |
| 11 | Effect offood or antacid on pharmacokinetics and pharmacodynamics offebuxostat in healthy subjects显示文摘 | KHOSRAVAN R GRABOWSKI BA WU JT et d | 2008 | Br J Clin Pharmacol2008，65，3： | 1 |
| 12 | The effect of mild and moderate hepatie impairment on phannacoki- netics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase显示文摘 | KHOSRAVAN R GRABOWSKI BA MAYER MD | 2006 | J Clin Phar- macol2006，46，1： | 1 |
| 13 | Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects显示文摘 | Khosravan R Grabowski BA Wu JT | 2007 | Br J Clin Pharmacol2007，65，： | 1 |
| 14 | Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects显示文摘 | Khosravan R Grabowski BA Wu JT | 2007 | Br J Clin Pharmacol2007，65，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员